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ERPS has been applied to 837 medicines. 576 medicines (69% of those analyzed) had 
a national average price higher than IRP and had some market power, and therefore 
their prices were regulated. They represent 80% of public expenditure in medicines 
not covered by the basic health care plan. The average price reduction for those 
medicines was 40%. 1) a) SCC between HHI and APR is -0,01,. and 2) SCC between 
number of competitors in a relevant market and APR is -0,05. ConClusions: EPRS 
could represent important savings to Colombian Health System. Deeper analysis on 
SCC is needed in order to improve ERPS. Nonetheless, preliminary analysis suggests 
that other variables besides HHI, such as countries with better purchasing practices, 
therapeutic class, types of diseases, should be taken into account.
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objeCtives: Herb-drug interactions are an important safety concern. This study 
was conducted regardingthe interaction between the herbal remedy Rosmarinus 
officinalis essential oil and drugs which metabolism involves cytochrome P450 
isoenzymes. Major components of essential oil of the rosemary are monoterpene 
derivatives(1,8-cineole, camphor, α -pinene, β -pinene, camphene, borneol and 
limonene) which selectively induce cytochrome P450 activity. The influence of 
Rosmarinus officinalis essential oil on pharmacodynamic effects of diazepam and 
pentobarbital on experimental animals was evaluated in the study. Methods: The 
study was performed on NMRI-Haan mice, which were divided into control and 
experimental groups, each group consisted of 6 animals. The experimental groups 
were pretreated with the essential oil in a dose of 10 µl/kg and 20 µl/kg, applied 
orally, as a single and seven-days lasting pretreatment. Control was treated with 
saline 10 ml/kg, orally. Interaction with pentobarbital was examined by pentobarbi-
tal-induced sleeping time test (pentobarbital was administered intraperitoneally, 40 
mg/kg b.w.). The interaction with diazepam was examined by rotarod test (diazepam 
was administered intramuscularly, 2,5 mg/kg b.w.). Results: Seven-days pretreat-
ment with Rosmarinus officinalis essential oil in the dose of 10 µl/kg, significantly 
reduced pentobarbital-induced sleeping time, compared to the control group, 
p< 0.05, while the single-dose pretreatment with Rosmarinus officinalis essential 
oil in the dose of 20 µl/kg, significantly prolonged sleeping time, compared to the 
control, p< 0.05. Both doses of essential oil, applied repeatedly, caused significantly 
longer retention of mice on the rotarod in the period between the fifth and tenth 
minute after the administration of diazepam, compared to the group received diaz-
epam only (control), p< 0.05. ConClusions: The results have shown a considerable 
influence of Rosmarinus officinalis essential oil on diazepam and pentobarbital 
pharmacodynamics, and the ability of this herbal remedy to cause interaction with 
conventional drugs.
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objeCtives: While the utilization of National Health Insurance (NHI) covered 
Chinese medications (CMs) increased for the past one decade, this study aimed to 
evaluate the use of high alert Chinese Medications (HACMs) and its contributing 
factors in Taiwan. Methods: The six potential HACMs (Màn Tuó Luó, Qi¨°n Niú 
Z¨«, Chu¨°n W¨±, Ti¨°n Nán X¨©ng, Fù Z¨«, Bàn Xià) were selected upon the evidence-
based reviews and expert discussions. The retrospective cohort study was conducted 
using two million random samples of Taiwan National Health Insurance Research 
Databases (NHIRDs). The number of prescriptions, average durations, and average 
doses for these six HACMs across different levels of hospitals (clinics, district hospi-
tals, regional hospitals, medical centers) were compared using descriptive statistics 
and ANOVA. The inferential analyses using Chi-square, t and logistic regression 
tests were performed to explore the factors associated with the use of specified 
HACMs. Results: Of 420,637 patients ever prescribed with CMs in 2007, 9.2% were 
ever prescribed with the six specified potential HACMs. While the average duration 
was 16.6±23.6 days for all HACM users, the most common used HACMs were Bàn Xià 
and Fù Z¨«. The traditional Chinese Medicine (TCM) clinics prescribed the majority of 
HACMs (90.8%) and their average doses were statistically significant higher than that 
in hospital settings. Those who were female, aged 65-74 year-old, middle income, 
with 10 to 39 more items of outpatient prescribed medications, with severe hepatic 
disorders and located in north region of Taiwan tended to use these HACMs, while 
those located in central region of Taiwan, made outpatient visits more than 2 times 
and more than 40 items of prescribed medications, and with chronic pulmonary 
diseases were less likely to use these HCAMs. ConClusions: While the TCM clinics 
tended to prescribed HACMs, more attention should be made toward them as well 
as those who possessed specific characteristics.
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objeCtives: To compare persistence among patients with infusion (IV) vs. sub-
cutaneous (SQ) biologic claims stratified by indication. Methods: This retrospec-
tive, observational analysis used national data from Symphony Health Solutions 
(SHS). Adults with their first (index) IV or SQ biologic claim (excluding rituximab) 
from July 2, 2009 to January 8, 2010, were identified. Proxy eligibility criteria included 
Surgery (726.7 days), Ophthalmic (487.6 days) and Gastroenterology/Urology (482.2 
days). Among the product categories “Ruibetsu” in Japan, the standard deviation of 
regulatory review time was the smallest for Tube and Catheters (348.5 days) and the 
largest in orthopedics products (769.6 days). ConClusions: According to the data 
analysis the review time and standard deviation of PMA and New Medical Device 
between two countries had no significant difference. Both in the United States and 
Japan, certain category medical device approval timing predictability is low such as 
General&Plastic Surgery in US and orthopedics products in Japan.
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objeCtives: Recent decision suggested that regulatory bodies, especially European 
Medicines Agency (EMA), might be more open to risk management, while payers, 
show high risk aversion, especially with drug prices increasing. The objective of the 
project was to document the potential antagonism between regulators and payers 
in Europe, illustrated by specific examples of market access decisions. Methods: 
A review of drugs which obtained a marketing authorization (MA) between 2010 and 
2012, and were subjected to a higher scrutiny by regulators and payers (oncology 
drugs, orphan drugs, drugs which received a conditional marketing authorization), 
was performed. Overall, five drugs (ipilimumab, ofatumumab, pixantrone, pirfeni-
done, abiraterone acetate) were selected and analyzed at EMA level and at payer 
level in 7 EU countries: France, the UK, Germany, Italy, Spain, The Netherlands and 
Sweden, for available public reports. Results: The EMA, despite not compelling 
evidence, considered the potential benefit of the drug to be outstanding enough 
to justify a MA provided the manufacturer is running specific additional clinical 
research (e.g. ofatumumab, pixantrone, pirfenidone). Payers require harder evidence 
than regulators, evidence of benefit for primary endpoints such as overall survival, 
comparative data with adequate comparator, robustness of methodology, effect 
size, transferability to clinical practice, etc. Overall, there were 2 ‘not recommended’ 
decisions, 3 ‘restricted’ approvals, 3 financial agreements and 1 pay for performance 
scheme that were identified at payers’ level. ConClusions: The development of 
risk management strategies allowed the product to rapidly obtain a MA. However, 
payers’ high risk aversion was a hurdle for market access of new drugs, delaying 
patient access to new therapy even with the use of some instruments such as 
conditional reimbursement.
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objeCtives: Prescription drug monitoring programs (PDMPs) are viewed as an 
effective tool to reduce prescription drug abuse, diversion, and doctor shopping. 
Despite perceived effectiveness, PDMP utilization by health care providers remains 
low. To improve effectiveness, health care professionals must access and utilize 
PDMP reports when making treatment decisions. Understanding characteristics of 
PDMPs users may assist in developing strategies to increase utilization. We identify 
characteristics of community pharmacists in Kentucky who utilize the Kentucky 
All Schedule Prescription Electronic Reporting (KASPER) program and determine if 
perceptions regarding KASPER’s impact and effectiveness are related to pharmacists’ 
characteristics. Methods: Surveys were mailed to 2,018 Kentucky pharmacists. 
Reminder postcards and surveys were sent two weeks after the initial mailing. 
Bivariate analyses examined relationships between respondent characteristics 
and practice site (independent versus chain) and practice location (rural versus 
urban). Logistic regression models (LRM) adjusted for years since licensure, con-
trolled substance (CS) dispensing volume, and perceived KASPER effectiveness 
estimated the odds ratio (OR) and 95% confidence intervals (CI) of KASPER utili-
zation by community pharmacists. Statistical analyses were conducted in Stata 
v12.0. The study was approved by the University of Kentucky Institutional Review 
Board. Results: Responses from 411 community pharmacists were included in the 
analysis. Results from LRM show that KASPER use varies significantly. Community 
pharmacists practicing in urban locations are 2.25 times more likely (CI: 1.11-4.57) 
to utilize KASPER than pharmacists in rural locations. Additionally, pharmacists 
practicing at independent pharmacies are 7.60 times more likely (CI: 3.20-18.05) to 
use KASPER than their counterparts practicing at chain pharmacies. The volume of 
CS dispensed nor perceived effectiveness of KASPER influenced the odds of KASPER 
utilization. ConClusions: Among community pharmacists, KASPER utilization 
varies and is influenced by pharmacists’ characteristics including practice site and 
practice location. Understanding characteristics of pharmacists who utilize PDMPs 
is necessary to remove barriers to access and increase utilization.
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bACkgRound: Very high prices of medicines have been observed in Colombia com-
pared to other countries; hence, a new external reference pricing system (ERPS) was 
adopted in 2013. ERPS includes three main phases: 1) Identification of relevant mar-
kets; 2) Analysis of market power using the Hirschman-Herfindahl index (HHI); and 
3)Setting-up of an international reference price (IRP) for each relevant market, using 
available information of wholesaler prices of 17 countries from the Americas, Europe 
and Australia. objeCtives: To evaluate Colombia’s EPRS. Methods: The ERPS will 
be evaluated through two different tools: 1) Through its impact on public health 
expenditure on medicines, and number of medicines regulated, and 2) Through 
the simple correlation coefficient (SCC) between a) HHI and average price reduction 
(APR), and b) Number of competitors in a relevant market and APR. Results: 1) 
